ArticleSingapore medical journal2017
Glioblastoma multiforme outcomes of 107 patients treated in two Singapore institutions.
Article in Singapore medical journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Blood-Nanoparticle Interactions Create a Brain Delivery Superhighway for Doxorubicin.International journal of nanomedicine · 2024Article
- Molecular Pathways Implicated in Radioresistance of Glioblastoma Multiforme: What Is the Role of Extracellular Vesicles?International journal of molecular sciences · 2023Review
- Long-Term Outcomes of Patients with Primary Brain Tumors after Acute Rehabilitation: A Retrospective Analyses of Factors.Life (Basel, Switzerland) · 2022Article
- Review
- Exploring the Interplay between Drug Release and Targeting of Lipid-Like Polymer Nanoparticles Loaded with Doxorubicin.Molecules (Basel, Switzerland) · 2021Article
- Epidemiology of Anthropometric Factors in Glioblastoma Multiforme-Literature Review.Brain sciences · 2021Review
- Molecular exploration of paediatric intracranial germinomas from multi-ethnic Singapore.BMC neurology · 2020Article
- Application of Electric Cell-Substrate Impedance Sensing to Investigate the Cytotoxic Effects of Andrographolide on U-87 MG Glioblastoma Cell Migration and Apoptosis.Sensors (Basel, Switzerland) · 2019Article
- Anticancer Effect of Cisplatin-Loaded Poly (Butylcyanoacrylate) Nanoparticles on A172 Brain Cancer Cells LineAsian Pacific journal of cancer prevention : APJCP · 2019Article
- Authors' reply.Singapore medical journal · 2017Article
- Comment on: Glioblastoma multiforme outcomes of 107 patients treated in two local institutions.Singapore medical journal · 2017Article
- Glioblastoma in the elderly: treatment patterns and survival.CNS oncology · 2017Article
- Cannabidiol Μay Prolong Survival in Patients With Glioblastoma Multiforme.Cancer diagnosis & prognosisArticle
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGlioblastoma multiforme (GBM) is the most common primary brain tumour in adults. Although the survival rate for GBM has improved with recent advancements in treatment, the prognosis remains generally poor.
methodsWe conducted a retrospective review of GBM patients seen in National University Hospital, Singapore, and Tan Tock Seng Hospital, Singapore, from January 2002 to December 2011. Data on disease and treatment factors was collected and correlated with survival.
resultsData on a total of 107 GBM patients was analysed. Their median survival time was 15.1 months and the two-year survival rate was 23.5%, which is comparable with data published in other series. The factors associated with improved median survival time were radiotherapy dose > 50 Gy (16.1 months vs. 8.7 months, p = 0.01) and adjuvant concurrent chemotherapy (16.4 months vs. 9.2 months, p = 0.003).
conclusionGBM confers a poor prognosis. Adjuvant radiotherapy and chemotherapy are associated with improved survival. Ethnicity may be a contributing factor to differences in GBM incidence and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.